These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 33313071)

  • 1. The Association of Introducing a Faecal Calprotectin Testing Pathway for Suspected Inflammatory Bowel Disease in Primary Care and Time to Diagnosis or Treatment.
    Hicks A; Hamlin PJ; Selinger CP
    Inflamm Intest Dis; 2020 Nov; 5(4):191-199. PubMed ID: 33313071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Kandala NB; Shyangdan D; Arasaradnam R; Clar C; Johnston R
    Health Technol Assess; 2013 Nov; 17(55):xv-xix, 1-211. PubMed ID: 24286461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unrestricted faecal calprotectin testing performs poorly in the diagnosis of inflammatory bowel disease in patients in primary care.
    Conroy S; Hale MF; Cross SS; Swallow K; Sidhu RH; Sargur R; Lobo AJ
    J Clin Pathol; 2018 Apr; 71(4):316-322. PubMed ID: 28844038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary care faecal calprotectin testing in children with suspected inflammatory bowel disease: a diagnostic accuracy study.
    Walker GJ; Chanchlani N; Thomas A; Lin S; Moore L; Heerasing NM; Hendy P; Abdelrahim M; Mole S; Perry MH; Mcdonald TJ; Bewshea CM; Hart JW; Russell RK; Ahmad T; Goodhand JR; Kennedy NA
    Arch Dis Child; 2020 Oct; 105(10):957-963. PubMed ID: 32424002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.
    Kuenzig ME; Benchimol EI; Lee L; Targownik LE; Singh H; Kaplan GG; Bernstein CN; Bitton A; Nguyen GC; Lee K; Cooke-Lauder J; Murthy SK
    J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S17-S33. PubMed ID: 31294382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical utility and diagnostic accuracy of faecal calprotectin for IBD at first presentation to gastroenterology services in adults aged 16-50 years.
    Kennedy NA; Clark A; Walkden A; Chang JC; Fascí-Spurio F; Muscat M; Gordon BW; Kingstone K; Satsangi J; Arnott ID; Lees CW
    J Crohns Colitis; 2015 Jan; 9(1):41-9. PubMed ID: 25135754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a faecal calprotectin care pathway for use in primary care.
    Turvill J; O'Connell S; Brooks A; Bradley-Wood K; Laing J; Thiagarajan S; Hammond D; Turnock D; Jones A; Sood R; Ford A
    Prim Health Care Res Dev; 2016 Sep; 17(5):428-36. PubMed ID: 26899214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Test accuracy of faecal calprotectin for inflammatory bowel disease in UK primary care: a retrospective cohort study of the IMRD-UK data.
    Freeman K; Taylor-Phillips S; Willis BH; Ryan R; Clarke A
    BMJ Open; 2021 Feb; 11(2):e044177. PubMed ID: 33619196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and cost-effectiveness of measuring fecal calprotectin in diagnosis of inflammatory bowel disease in adults and children.
    Yang Z; Clark N; Park KT
    Clin Gastroenterol Hepatol; 2014 Feb; 12(2):253-62.e2. PubMed ID: 23883663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Negative Effects on Psychological Health and Quality of Life of Genuine Irritable Bowel Syndrome-type Symptoms in Patients With Inflammatory Bowel Disease.
    Gracie DJ; Williams CJ; Sood R; Mumtaz S; Bholah MH; Hamlin PJ; Ford AC
    Clin Gastroenterol Hepatol; 2017 Mar; 15(3):376-384.e5. PubMed ID: 27189912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Faecal calprotectin effectively excludes inflammatory bowel disease in 789 symptomatic young adults with/without alarm symptoms: a prospective UK primary care cohort study.
    Walker GJ; Moore L; Heerasing N; Hendy P; Perry MH; McDonald TJ; Debenham T; Bethune R; Bewshea C; Hyde C; Heap GA; Singh A; Calvert C; Kennedy NA; Goodhand JR; Ahmad T
    Aliment Pharmacol Ther; 2018 Apr; 47(8):1103-1116. PubMed ID: 29508423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice.
    Reenaers C; Bossuyt P; Hindryckx P; Vanpoucke H; Cremer A; Baert F
    United European Gastroenterol J; 2018 Oct; 6(8):1117-1125. PubMed ID: 30288273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does faecal calprotectin differentiate between inflammatory bowel disease colitis and non-inflammatory bowel disease colitides?
    Khalil AF; Helmy EM; Massoud MN; Baddour NM; Metwally RH; Omar OM
    Prz Gastroenterol; 2021; 16(3):219-223. PubMed ID: 34584583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical usefulness of the faecal calprotectin test in suspected paediatric inflammatory bowel disease.
    Akobeng AK
    Acta Paediatr; 2018 Nov; 107(11):2019-2023. PubMed ID: 29706011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safely ruling out inflammatory bowel disease in children and teenagers without referral for endoscopy.
    Van de Vijver E; Schreuder AB; Cnossen WR; Muller Kobold AC; van Rheenen PF;
    Arch Dis Child; 2012 Dec; 97(12):1014-8. PubMed ID: 23019289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease.
    Henderson P; Casey A; Lawrence SJ; Kennedy NA; Kingstone K; Rogers P; Gillett PM; Wilson DC
    Am J Gastroenterol; 2012 Jun; 107(6):941-9. PubMed ID: 22370604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease.
    Rosenfeld G; Greenup AJ; Round A; Takach O; Halparin L; Saadeddin A; Ho JK; Lee T; Enns R; Bressler B
    World J Gastroenterol; 2016 Sep; 22(36):8211-8. PubMed ID: 27688663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes at 12 months and risk of inflammatory bowel disease in patients with an intermediate raised fecal calprotectin: a 'real-world' view.
    McFarlane M; Chambers S; Malik A; Lee B; Sung E; Nwokolo C; Waugh N; Arasaradnam R
    BMJ Open; 2016 Jun; 6(6):e011041. PubMed ID: 27266773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.
    Chang MH; Chou JW; Chen SM; Tsai MC; Sun YS; Lin CC; Lin CP
    Mol Med Rep; 2014 Jul; 10(1):522-6. PubMed ID: 24788223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Audit of the impact of the York faecal calprotectin care pathway on colonoscopy activity.
    Turvill J; Turnock D
    Frontline Gastroenterol; 2020; 11(4):285-289. PubMed ID: 32587672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.